Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 5Recruiting 2Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 28Stomach Neoplasms 21Pancreatic Neoplasms 14Colonic Neoplasms 14Rectal Neoplasms 9Esophageal Neoplasms 8Lymphoma, Large B-Cell, Diffuse 7Adenocarcinoma Of Esophagus 7Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Cholangiocarcinoma 4Adenocarcinoma 4Ovarian Neoplasms 3Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma, Follicular 2Hepatoblastoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unresectable Colorectal Cancer 1Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Solid Cancer 1Skin Neoplasms 1Recurrence 1

Interventions

Capecitabine 2Bevacizumab 2trifluridine tipiracil drug combination 1sintilimab 1atezolizumab 1Transurethral Resection of Prostate 1Tomography, X-Ray Computed 1Oxaliplatin 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Colorectal Cancer Metastatic × Oxaliplatin × Clear all
NCT04940546 2024-12-03

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

Sun Yat-sen University

Phase 1/2 Active not recruiting
36 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡